C Pinto

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
    C Pinto
    Division of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 24:143-7. 2001
  2. ncbi Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study)
    F Rojas Llimpe
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy General and Liver Surgery Unit, S Orsola Malpighi, Bologna, Italy Radiology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy Nuclear Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 27:e15010. 2009
  3. ncbi Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    C Pinto
    S Orsola Malpighi Hospital, Bologna, Italy Gemelli Hospital, Rome, Italy Medical Oncology Falck Unit, Niguarda Ca Granda Hospital, Milan, Italy General Hospital, Livorno, Italy University of Marche, Umberto I Hospital, Ancona, Italy
    J Clin Oncol 26:4575. 2008
  4. ncbi Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
    C Aschele
    E O Galliera, Genova, Italy A O S Orsola Malpighi, Bologna, Italy S Luigi Santo Currò, Catania, Italy A O S Carlo, Potenza, Italy A S L 1, Carrara, Italy Ospedale Niguarda Cà Granda, Milano, Italy Ospedale Morgagni Pierantoni, Forli, Italy Istituto Oncologico Veneto, Padova, Italy Istituto Toscano Tumori, Firenze, Italy A O S Chiara, Pisa, Italy
    J Clin Oncol 27:CRA4008. 2009
  5. ncbi Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Oncology Unit, IRCCS Casa Sollievo, S Giovanni Rotondo, Italy Medical Oncology Unit, Galliera Hospital, Genoa, Italy Medical Oncology Unit, Regina Elena Institute, Rome, Italy Medical Oncology Unit, CROB, Rionero in Vulture, Italy Medical Oncology Unit, Macchi Hospital, Varese, Italy
    J Clin Oncol 27:4110. 2009
  6. ncbi Vitamin K1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: First analysis of an observational Italian study
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy Catholic University of Sacred Heart, Rome, Italy Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
    J Clin Oncol 29:594. 2011
  7. ncbi Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy
    F Di Fabio
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Nuclear Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Physics Unit, S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 27:e15601. 2009
  8. ncbi Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial
    F De Vita
    Second University of Naples, Naples, Italy CRO Aviano, Aviano, Italy Medical Oncology, Bologna, Italy Medical Oncology, Padova, Italy Surgical Oncology, Padova, Italy
    J Clin Oncol 26:15524. 2008
  9. doi Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, Bologna, Italy
    Ann Oncol 22:2424-30. 2011
  10. ncbi Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy
    C Funaioli
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Oncology and Hematology Department, University of Modena and Reggio Emilia, Modena, Italy Medical Oncology Unit, University Campus Bio Medico, Rome, Italy
    J Clin Oncol 26:14631. 2008

Collaborators

Detail Information

Publications24

  1. ncbi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
    C Pinto
    Division of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 24:143-7. 2001
    ..8%, 13.6%, and 22.7% of patients, respectively. From the data presented here, this regimen can be considered active in the treatment of malignant pleural mesothelioma...
  2. ncbi Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study)
    F Rojas Llimpe
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy General and Liver Surgery Unit, S Orsola Malpighi, Bologna, Italy Radiology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy Nuclear Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 27:e15010. 2009
    ..e15010 Background: The aim of the study was to define the specific diagnostic accuracy of different imaging techniques in patients (pts) with resectable colorectal cancer liver metastasis (CLMs)...
  3. ncbi Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    C Pinto
    S Orsola Malpighi Hospital, Bologna, Italy Gemelli Hospital, Rome, Italy Medical Oncology Falck Unit, Niguarda Ca Granda Hospital, Milan, Italy General Hospital, Livorno, Italy University of Marche, Umberto I Hospital, Ancona, Italy
    J Clin Oncol 26:4575. 2008
    ..4575 Background: The aim of this study was to evaluate the efficacy and safety of cetuximab in combination with cisplatin and docetaxel as first-line treatment for advanced gastric or GEJ cancer...
  4. ncbi Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
    C Aschele
    E O Galliera, Genova, Italy A O S Orsola Malpighi, Bologna, Italy S Luigi Santo Currò, Catania, Italy A O S Carlo, Potenza, Italy A S L 1, Carrara, Italy Ospedale Niguarda Cà Granda, Milano, Italy Ospedale Morgagni Pierantoni, Forli, Italy Istituto Oncologico Veneto, Padova, Italy Istituto Toscano Tumori, Firenze, Italy A O S Chiara, Pisa, Italy
    J Clin Oncol 27:CRA4008. 2009
    ..This randomized phase III trial investigated the effect of adding OXA to preoperative (preop) FU-based pelvic chemoradiation (CRT) in patients (pts) with locally-advanced rectal cancer...
  5. ncbi Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Oncology Unit, IRCCS Casa Sollievo, S Giovanni Rotondo, Italy Medical Oncology Unit, Galliera Hospital, Genoa, Italy Medical Oncology Unit, Regina Elena Institute, Rome, Italy Medical Oncology Unit, CROB, Rionero in Vulture, Italy Medical Oncology Unit, Macchi Hospital, Varese, Italy
    J Clin Oncol 27:4110. 2009
    ..4110 Background: The aim of this phase II study is to assess the activity of preoperative external radiotherapy combined with panitumumab, oxaliplatin and 5-fluorouracil in locally advanced rectal cancer patients (pts)...
  6. ncbi Vitamin K1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: First analysis of an observational Italian study
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy Catholic University of Sacred Heart, Rome, Italy Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
    J Clin Oncol 29:594. 2011
    ..Preclinical studies have shown that vitamin K1 reactivated EGFR-mediated signal transduction after inhibition via EGFR receptor antagonists. The aim of this study was to evaluate the impact of vitamin K1 cream in skin rash management...
  7. ncbi Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy
    F Di Fabio
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Nuclear Medicine Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Physics Unit, S Orsola Malpighi Hospital, Bologna, Italy
    J Clin Oncol 27:e15601. 2009
    ..The aim of this study is to evaluate the usefulness of an early change in PET at several time-points in predicting response to cetuximab-containing therapy in pts with advanced GEJ or G cancer...
  8. ncbi Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial
    F De Vita
    Second University of Naples, Naples, Italy CRO Aviano, Aviano, Italy Medical Oncology, Bologna, Italy Medical Oncology, Padova, Italy Surgical Oncology, Padova, Italy
    J Clin Oncol 26:15524. 2008
    ..In EC, increased EGFR expression correlates with a worse prognosis in terms of shorter DFS and OS suggesting the possibility of treatment with anti- EGFR mAb Cetuximab (C)...
  9. doi Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, Bologna, Italy
    Ann Oncol 22:2424-30. 2011
    ..The aim of this phase II study was to assess the activity of panitumumab in combination with oxaliplatin, 5-fluorouracil, and external radiotherapy (RT) as preoperative treatment in locally advanced rectal cancer patients...
  10. ncbi Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy
    C Funaioli
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Oncology and Hematology Department, University of Modena and Reggio Emilia, Modena, Italy Medical Oncology Unit, University Campus Bio Medico, Rome, Italy
    J Clin Oncol 26:14631. 2008
    ..The aim of this study was to evaluate the recurrence of electrolytic imbalances and, in particular, of hypokalemia in pts treated with regimens including cetuximab or panitumumab...
  11. ncbi KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients
    G Stella
    Institute for Cancer Research and Treatment, Candiolo, Italy Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Oncology Unit, Gemelli Hospital, Rome, Italy Medical Oncology Unit, General Hospital, Livorno, Italy Pathology Unit, S Orsola Malpighi Hospital, Bologna, Italy Medical Oncology Unit, Niguarda Ca Granda, Milan, Italy
    J Clin Oncol 27:e15503. 2009
    ..We have assessed whether, and to what extent, the mutational profile of KRAS and BRAF genes affects the response to cetuximab combination therapy in GC...
  12. ncbi Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab + irinotecan as predictive factor of efficacy and outcome
    B Vincenzi
    University Campus Bio Medico, Rome, Italy S Orsola Malpighi, Bologna, Italy
    J Clin Oncol 26:4106. 2008
    ....
  13. ncbi Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients: Italian SoMe Study
    V Mutri
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy Oncology Department, Mario Negri Institute, Milan, Italy
    J Clin Oncol 29:7087. 2011
    ..7087 Background: This phase I study investigated the safety and efficacy of sorafenib in combination with cisplatin and pemetrexed in untreated MPM patients (pts)...
  14. pmc A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
    F De Vita
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
    Br J Cancer 104:427-32. 2011
    ..Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared with surgery alone...
  15. ncbi A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC)
    F De Vita
    Second University of Naples, Naples, Italy CRO Aviano, Aviano, Italy Azienda Ospedaliera, Bologna, Italy Azienda Ospedaliera, Padova, Italy University of Padova, Padova, Italy
    J Clin Oncol 27:4546. 2009
    ..The purpose of the study was to investigate the efficacy, toxicity and feasibility of C with FOLFOX- 4 regimen as induction CT followed by C and RT in pts with LAEC in a multicenter setting...
  16. ncbi Topical vitamin K1 in the management of skin rash during anti-EGFR monoclonal antibody treatment in patients with metastatic cancer: Italian Observational Study
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy Medical Oncology, San Paolo Hospital, Milan, Italy Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    J Clin Oncol 29:e14068. 2011
    ..The aim of this study was to evaluate the impact of vitamin K1 cream in skin rash management...
  17. ncbi Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study
    A Martoni
    U O di Oncologia Medica, Dipartimento di Oncologia e Ematologia, Policlinico S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    Anticancer Res 23:687-91. 2003
    ..The median time to progression was 5 months (2-11). The median survival was not reached after a median follow-up of 14 months. One-year survival is 60%...
  18. ncbi Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
    C Aschele
    E O Galliera, Genova, Italy A O S Orsola Malpighi, Bologna, Italy S Luigi Santo Currò, Catania, Italy A O S Carlo, Potenza, Italy A S L 1, Carrara, Italy Ospedale Niguarda Cà Granda, Milano, Italy Ospedale Morgagni Pierantoni, Forli, Italy Istituto Oncologico Veneto, Padova, Italy Istituto Toscano Tumori, Firenze, Italy A O S Chiara, Pisa, Italy
    J Clin Oncol 27:CRA4008. 2009
    ..No significant financial relationships to disclose...
  19. ncbi Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study)
    F Di Fabio
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna, Italy Centre Study of Biological Markers of Malignancy, IOV IRCCS ABO, Venice, Italy Centre Study of Biological Markers of Malignancy, Venice, Italy
    J Clin Oncol 26:15605. 2008
    ..15605 Background: The aim of this study was to evaluate the predictive significance of circulating VEGF modifications in advanced gastric or GEJ cancer pts treated with cetuximab plus cisplatin and docetaxel as first-line therapy...
  20. ncbi Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma
    A Martoni
    Department of Oncology and Haematology, S. Orsola-Malpighi Hospital, Bologna, Italy
    Ann Oncol 12:519-24. 2001
    ....
  21. pmc Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study
    F L Rojas Llimpe
    Medical Oncology Unit, S Orsola Malpighi Hospital, Bologna 40138, Italy
    Br J Cancer 111:667-73. 2014
    ..The aim of the PROMETEO-01 Study was to define the diagnostic accuracy of imaging techniques in colorectal cancer liver metastasis (CRCLM) patients...
  22. pmc Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009
    ..The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma...
  23. ncbi Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
    ..The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma...
  24. pmc MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease
    C Pinto
    Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
    Br J Cancer 95:752-6. 2006
    ..Further studies are warranted to understand the genetic and environmental factors responsible for the variable penetration of MSH6 germline mutations, as well as to identify other causes of early-onset colorectal cancer...